Equities analysts predict that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will post ($0.21) earnings per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.22). Infinity Pharmaceuticals posted earnings per share of ($0.14) in the same quarter last year, which suggests a negative year over year growth rate of 50%. The company is scheduled to issue its next quarterly earnings report on Thursday, March 12th.
On average, analysts expect that Infinity Pharmaceuticals will report full-year earnings of ($0.83) per share for the current fiscal year, with EPS estimates ranging from ($0.85) to ($0.81). For the next year, analysts expect that the company will post earnings of ($0.90) per share, with EPS estimates ranging from ($0.96) to ($0.83). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Infinity Pharmaceuticals had a negative net margin of 1,519.91% and a negative return on equity of 125.37%. The business had revenue of $0.34 million during the quarter, compared to analyst estimates of $0.85 million.
Shares of INFI opened at $1.17 on Wednesday. The company has a current ratio of 6.22, a quick ratio of 6.22 and a debt-to-equity ratio of 0.11. Infinity Pharmaceuticals has a 12 month low of $0.82 and a 12 month high of $1.95. The stock’s 50 day moving average is $1.15 and its two-hundred day moving average is $1.23. The firm has a market cap of $66.72 million, a P/E ratio of -5.85 and a beta of 1.82.
Several large investors have recently modified their holdings of INFI. Renaissance Technologies LLC boosted its stake in shares of Infinity Pharmaceuticals by 12.4% in the second quarter. Renaissance Technologies LLC now owns 1,002,006 shares of the biotechnology company’s stock worth $1,804,000 after acquiring an additional 110,806 shares during the last quarter. Parametric Portfolio Associates LLC acquired a new stake in shares of Infinity Pharmaceuticals in the second quarter worth approximately $76,000. Evercore Wealth Management LLC boosted its stake in shares of Infinity Pharmaceuticals by 20.7% in the second quarter. Evercore Wealth Management LLC now owns 143,138 shares of the biotechnology company’s stock worth $258,000 after acquiring an additional 24,553 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of Infinity Pharmaceuticals by 5.0% in the second quarter. Jacobs Levy Equity Management Inc. now owns 201,438 shares of the biotechnology company’s stock worth $363,000 after acquiring an additional 9,511 shares during the last quarter. 51.46% of the stock is currently owned by hedge funds and other institutional investors.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Further Reading: What is the S&P/TSX Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.